| ptxP1/fhaB3-ER | ptxP3/fhaB2-ESa | ptxP1/fhaB2-ES | χ2 | P |
---|
n = 403(%) | n = 21(%) | n = 9(%) |
---|
Age (Months)b | 3 (2–5.5) | 2 (1–3.5) | 3 (2–5) | 1.479c | 0.225 |
Vaccination statusd | | | | 6.87 | 0.032 |
Vaccinated | 133 (33.0) | 2 (9.5) | 1 (11.1) |
Unvaccinated | 270 (67.0) | 19 (90.5) | 8 (88.9) |
- aThe ptxP3-ES with proportions of 8.93, 9.38, 6.19, 2.65 and 3.09% from 2012 to 2016 in this study
- bThe ages were represented as Med, x.5 (Q1, x.25- Q3, x.75)
- cRefers to the F value with ANOVA test between ptxP1-ER and ptxP3-ES group
- dThe cases of unclear vaccination status were not enrolled, what was 46 and 1 in ptxP1-ER and ptxP3-ES group each. All the vaccinated group administrated with the Co-aPV